Highest-materiality recent filing
Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027
Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).
Acumen stockholders elect three Class II directors, approve equity plan
Elected Golumbeski (37.3M for), Porter (30.9M for), Stoppel (30.8M for) as Class II directors.
Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026
Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.
Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026
Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.
Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration
Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.
Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition
Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.
Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027
Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.
Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort
Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.
Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026
Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.
Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones
JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.
Acumen shareholders elect three Class I directors, ratify EY as auditor
Elected Kimberlee C. Drapkin, Jeffrey Ives, and Sean Stalfort as Class I directors until 2028 with ~30M votes each; ~17.5M broker non-votes.
Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026
Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.
Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete
Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.
Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025
Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).
Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations
Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.
Acumen stockholders elect two Class III directors, ratify Ernst & Young as auditor for FY2024
Daniel O'Connell received 40,490,834 votes for, 48,338 withheld; Nathan Fountain 34,164,444 for, 6,371,549 withheld.
Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated
Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.
Acumen Pharma FY2023 net loss $52.4M; cash $306.1M; Phase 2 AD trial to start H1 2024
Net loss $52.4M in FY2023 vs $42.9M in 2022; operating loss $61.1M.
Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study
Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).
Acumen appoints Dr. James Doherty as President and Chief Development Officer
Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.
Acumen Pharmaceuticals posts updated corporate presentation; no material new information disclosed
Filed under Item 7.01; presentation posted to company website on January 12, 2024.
Company posted updated corporate presentation on its website with additional biomarker data for ACU193.
Updated corporate presentation posted to investor website on December 4, 2023.
Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility
Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.
Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility
Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.
Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront
Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.
Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).
Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share
Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.
Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate
60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.
Company plans to offer shares of common stock; no terms disclosed.
Acumen shareholders approve officer exculpation amendment; re-elect directors
Shareholders approved certificate amendment to allow officer exculpation per Delaware law (27,061,448 votes for, 99.9% of votes cast).
Acumen Q1 net loss $11.3M; cash $183.8M; Phase 1 ACU193 topline due Q3 2023
Net loss of $11.3M for Q1 2023 vs $9.1M in Q1 2022; no revenue reported.
Acumen adds BTIG as ATM sales agent; $4.25M of $50M capacity used as of April 26
Added BTIG, LLC as a sales agent under the existing at-the-market (ATM) offering agreement.
Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023
Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.
Acumen amends bylaws to adopt universal proxy rules and DGCL updates
Board adopted amended bylaws effective March 9, 2023, to comply with SEC Rule 14a-19 (universal proxy) and recent DGCL changes.
Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7
Expects enrollment completion Q1 2023, topline data Q3 2023.
Acumen appoints Dr. Derrell Porter to board effective Jan. 4, 2023
Dr. Porter appointed as Class II independent director; named to Nominating and Governance Committee.
Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted
Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.
Acumen's ACU193 receives FDA Fast Track designation for early Alzheimer's disease
ACU193 is first clinical-stage monoclonal antibody selectively targeting toxic soluble amyloid beta oligomers (AßOs).
Acumen posts updated corporate presentation on website; no new material data disclosed
Company posted updated corporate presentation dated September 2022 to its investor website on September 12, 2022.
Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns
Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.
Acumen presents ADDL assay method to standardize AßO testing for Alzheimer's therapeutics
Presented poster at AAIC 2022 on using ADDLs as synthetic AßO reference standard for bioanalytical assays.
Acumen shareholders elect all director nominees and ratify E&Y as auditor at annual meeting
All three Class I director nominees elected: Kimberlee C. Drapkin, Jeffrey Ives (Ph.D.), Sean Stalfort; broker non-votes of 5,658,008.
Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025
Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.
Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023
Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.
CEO O'Connell: $551,200 base salary; 55% bonus target; 12-month non-CIC severance, 18-month CIC severance.
Acumen Q3 loss $3.9M, cash $229.9M; ACU193 Phase 1 trial enrolling
Net loss $3.9M (Q3), $92.3M (9M) including $80.3M non-cash fair-value charges from preferred stock and warrant liabilities.
Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease
ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.
Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's
First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.
Acumen posts updated corporate presentation; no specific financial data disclosed
Updated corporate presentation posted to investor website on August 31, 2021.
James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.
Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.
On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).
On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event other_material